Comparative safety, immunogenicity, and efficacy of several anti-H5N1 influenza experimental vaccines in a mouse and chicken models (Testing of killed and live H5 vaccine)

Influenza and other Respiratory Viruses

Volumn 6, Issue 3, 2012, Pages 188-195

  Gambaryan, Alexandra S ^a   Lomakina, Natalia F ^b   Boravleva, Elizaveta Y ^a   Kropotkina, Ekaterina A ^a   Mashin, Vadim V ^c   Krasilnikov, Igor V ^c   Klimov, Alexander I ^d   Rudenko, Larisa G ^e  

^a CHUMAKOV INSTITUTE OF POLIOMYELITIS AND VIRAL ENCEPHALITIDES   (Russian Federation)

^b Russian Academy of Agricultural Sciences   (Russian Federation)

^c N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e INSTITUTE OF EXPERIMENTAL MEDICINE   (Russian Federation)

Author keywords

H5N1; Live attenuated influenza vaccine

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; EMBRYO; IMMUNOGENICITY; INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H5N1; LOW DRUG DOSE; MORTALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS STRAIN; VIRUS SURVIVAL; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, VIRAL; CHICKENS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; VACCINES, ATTENUATED; VACCINES, INACTIVATED;

EID: 84859740087     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2011.00291.x     Document Type: Article

References (34)

1. Cox RJ, Hovden AO, Brokstad KA, Szyszko E, Madhun AS, Haaheim LR. The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice. Vaccine 2006; 24:6585-6587.
2. Subbarao K, Chen H, Swayne D et al. Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. Virology 2003; 305:192-200.
3. Alexandrova GI, Polezhaev FI, Budilovsky GN et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccines. Infect Immun 1984; 44:734-739.
4. Steel J, Lowen AC, Pena L et al. Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol 2009; 83:1742-1753.
5. Suguitan AL Jr, McAuliffe J, Mills KL et al. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 2006; 3:1541-1554.
6. Desheva JA, Lu XH, Rekstin AR et al. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 2006; 24:6859-6866.
7. Palese P, Shaw ML. Orthomyxoviridae: the viruses and their replication; in Knipe DM, Howley PM (eds): Fields Virology, 5th edn, vol. II. Philadelphia, PA: Lippincott Williams and Wilkins, 2006; 1648-1689.
8. Fodor E, Devenish L, Engelhardt OG, Palese P, Brownlee GG, Garcia-Sastre A. Rescue of influenza A virus from recombinant DNA. J Virol 1999; 73:9679-9682.
9. Hatta M, Gao P, Halfmann P, Kawaoka Y. Molecular basis for high virulence of Hong Kong H5N1 influenza A viruses. Science 2001; 293:1840-1842.
10. Gabriel G, Dauber B, Wolff T, Planz O, Klenk H-D, Stech J. The viral polymerase mediates adaptation of an avian influenza virus to a mammalian host. PNAS 2005; 102:18590-18595.
11. Garcia-Sastre A, Biron CA. Type 1 interferons and the virus-host relationship: a lesson in detente. Science 2006; 312:879-882.
12. Hai R, Martínez-Sobrido L, Fraser KA, Ayllon J, García-Sastre A, Palese P. Influenza B virus NS1-truncated mutants: live-attenuated vaccine approach. J Virol 2008; 82:10580-10590.
13. Wang L, Suarez DL, Pantin-Jackwood M et al. Characterization of influenza virus variants with different sizes of the non-structural (NS) genes and their potential as a live influenza vaccine in poultry. Vaccine 2008; 26:3580-3586.
14. Wang L, Yassine H, Saif YM, Lee CW. Developing live attenuated avian influenza virus in ovo vaccines for poultry. Avian Dis 2010; 54(1 Suppl):297-301.
15. Richt JA, Lekcharoensuk P, Lager KM et al. Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. J Virol 2006; 80:11009-11018.
16. Vincent AL, Ma W, Lager KM et al. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 2007; 25:7999-8009.
17. Gabriel G, Garn H, Wegmann M et al. The potential of a protease activation mutant of a highly pathogenic avian influenza virus for a pandemic live vaccine. Vaccine 2008; 26:956-965.
18. Suguitan AL Jr, Marino MP, Desai PD et al. The influence of the multi-basic cleavage site of the H5 hemagglutinin on the attenuation, immunogenicity and efficacy of a live attenuated influenza A H5N1 cold-adapted vaccine virus. Virology 2009; 395:280-288.
19. Murphy BR, Sly DL, Tierney EL et al. Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. Science 1982; 218:1330-1332.
20. Subbarao K, Webster RG, Kawaoka Y, Murphy BR. Are there alternative avian influenza viruses for generation of stable attenuated avian-human influenza A reassortant viruses? Virus Res 1995; 39:105-118.
21. Lomakina NF, Gambaryan AC, Boravleva EY et al. Character of apathogenic influenza A viruses found in Moscow, Russia. Mol Gen Microbiol Virol 2009; 24:37-45.
22. Lomakina NF, Boravleva EY, Kropotkina EA, Yamnikova SS, Drygin VV, Gambaryan AS. Attenuation of A/chicken/Kurgan/3/2005 (H5N1) influenza virus by selection in an environment simulating a life cycle of wild duck viruses. Mol Gen Microbiol Virol 2011; 26:132-139.
23. Danesh-Bahreini MA, Shokri J, Samiei A, Kamali-Sarvestani E, Barzegar-Jalali M, Mohammadi-Samani S. Nanovaccine for leishmaniasis: preparation of chitosan nanoparticles containing Leishmania superoxide dismutase and evaluation of its immunogenicity in BALB/c mice. Int J Nanomedicine 2011; 6:835-842.
24. Gambaryan AS, Boravleva EY, Matrosovich TY et al. Polymer-bound 6′ sialyl-N-acetyllactosamine protects mice infected by influenza virus. Antiviral Res 2005; 68:116-123.
25. Gambaryan AS, Tuzikov AB, Pazynina GV et al. 6-sulfo sialyl Lewis X is the common receptor determinant recognized by H5, H6, H7 and H9 influenza viruses of terrestrial poultry. Virol J 2008; 5:85 PMID: 18652681.
26. Elton D, Medcalf L, Bishop K, Harrison D, Digard P. Identification of amino acid residues of influenza virus nucleoprotein essential for RNA binding. J Virol 1999; 73:7357-7367.
27. Greenspan D, Palese P, Krystal M. Two nuclear location signals in the influenza virus NS1 nonstructural protein. J Virol 1988; 62:3020-3026.
28. Reed ML, Yen HL, DuBois RM et al. Amino acid residues in the fusion peptide pocket regulate the pH of activation of the H5N1 influenza virus hemagglutinin protein. J Virol 2009; 83:3568-3580.
29. Brown EG, Liu H, Chang Kit L, Baird S, Nesrallah M. Pattern of mutation in the genome of influenza A virus on adaptation to increased virulence in the mouse lung: identification of functional themes. Proc Natl Acad Sci U S A 2001; 98:6883-6888.
30. Hsu CN, Wang CH. Sequence comparison between two quasi strains of H6N1 with different pathogenicity from a single parental isolate. J Microbiol Immunol Infect 2006; 39:292-296.
31. Reed ML, Bridges OA, Seiler P et al. The pH of activation of the hemagglutinin protein regulates H5N1 influenza virus pathogenicity and transmissibility in ducks. J Virol 2010; 84:1527-1535.
32. Kreijtz JH, Bodewes R, van Amerongen G et al. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 2007; 25:612-620.
33. Seo SU, Byun YH, Lee EY et al. Development and characterization of a live attenuated influenza B virus vaccine candidate. Vaccine 2008; 26:874-881.
34. Capua I, Terregino C, Cattoli G, Mutinelli F, Rodriguez JF. Development of a DIVA (differentiating infected from vaccinated animals) strategy using a vaccine containing a heterologous neuraminidase for the control of avian influenza. Avian Pathol 2003; 32:47-55.